#ASH17: Blueprint elbows its way to center ring with early data and a plan to seek quick FDA OK
Blueprint Medicines $BPMC jumped onto the radar at ASH on Sunday, outlining some remarkable data on their lead drug as the biotech lays the foundation for a registration program with the FDA. The Cambridge, MA-based biotech, which went public in 2015 and has a market cap that’s grown to $2.8 billion, definitely wants to get the word out.
Investigators for the company reported that their lead drug — avapritinib, formerly known as BLU-285 — hit an impressive 72% overall response rate for rare cases of advanced systemic mastocytosis and a 100% disease control rate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.